Stay updated on RO6958688 Combination with Atezolizumab in CEA+ Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the RO6958688 Combination with Atezolizumab in CEA+ Solid Tumors Clinical Trial page.

Latest updates to the RO6958688 Combination with Atezolizumab in CEA+ Solid Tumors Clinical Trial page
- Check6 days agoChange DetectedThe footer now displays site revision v3.7.2 instead of v3.7.1. The page remains a 403 error page.SummaryDifference0.2%

- Check13 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1; the study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedRemoval of the 403 Forbidden text and the Home link indicates the error state was cleared. The study details content is now accessible.SummaryDifference0.5%

- Check34 days agoChange DetectedThe page now displays a 403 Forbidden error page (with a Home link and site footer), replacing the prior study record content and signaling an access block rather than a data update.SummaryDifference19%

- Check55 days agoChange DetectedNIH grant/contract information was added to the study's identifiers, and the page revision tag was updated from v3.6.5 to v3.6.6, reflecting editorial/version updates on the page.SummaryDifference0.1%

- Check77 days agoChange DetectedThe page now shows an updated revision label, v3.6.5, replacing the previous v3.6.4, indicating a small update to the page's versioning.SummaryDifference0.1%

Stay in the know with updates to RO6958688 Combination with Atezolizumab in CEA+ Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the RO6958688 Combination with Atezolizumab in CEA+ Solid Tumors Clinical Trial page.